Biotech company Definium Therapeutics announced Monday that its LSD-derived medication, DT120, showed meaningful benefits for depression in a major clinical trial. According to io9, patients who received the treatment experienced lasting improvements in their depressive symptoms—significantly outperforming those given placebo. The result marks a pivotal moment for psychedelic medicine: decades after the compound was prohibited, researchers are now methodically proving its therapeutic potential in clinical settings.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton